 Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32 and beating sell-side expectations by 8. Management announced that 104 failed to show meaningful efficacy in a Phase II proof-of-concept study, and the company has few near-term clinical catalysts. 